Description

Attention-deficit hyperactivity disorder, commonly referred to as ADHD, is the primary diagnosis of the patient presented for the Mental Health Case Study Discussion. For this diagnosis, it is recommended to use the DSM-5 criteria (CDC, 2023). Current clinical practice guidelines also state that essentials of diagnosis include symptoms interfering with daily function and symptoms start before the age of twelve in at least two settings (Papadakis, et al., 2024). The first-line drug treatment used for ADHD is methylphenidate, and will be ordered as such: five- milligram tablets; take one tablet by mouth twice daily before breakfast and lunch; dispense sixty; zero refills (Papadakis, et al., 2024). Nonpharmacologic interventions for this patient being diagnosed with ADHD, includes psychoeducation and cognitive behavioral therapy. These two nonpharmacologic interventions focus on implementing behavioral changes that allows the patient to better function, such as utilizing calendars or planners, completing tasks in short-timed intervals, and creating to-do lists (Papadakis, et al., 2024). This patient is recommended to follow-up in one month for re-evaluation of symptoms and further treatment management. This includes evaluating medication effectiveness and the need for dose increase or change to extended release. A psychiatric referral may be placed for further nonpharmacologic intervention and management of ADHD……. Continue